For the Inventor, By the Inventor

Enter inventor name

Andrés Avelino Trabanco-Suárez

USPTO Granted Patents = 53 (Patent Applications = 22)

CIPO Patents = 25 (Patent Applications = 16)

EPO Patents = 32 (Patent Applications = 29)

Average Co-Inventor Count = 4.9

ph-index = 5

Forward Citations = 158(Granted Patents)

Forward Citations (Not Self Cited) = 79(Dec 10, 2025)

Location History:

Olias del Ray, ES (2012 - 2015)
Madrid, ES (2016)
Olias del Rey (Toledo), ES (2015 - 2018)
Toledo, ES (2011 - 2021)
Olias del Rey, ES (2010 - 2024)

Company Filing History:

27 out of 2,079

Janssen Pharmaceutica Nv

Janssen Pharmaceuticals, Inc.

Addex Pharma, S.a.

Addex Pharmaceuticals S.a.

where one patent can have more than one assignee

Years Active: 2010-2024

Loading Chart...

Loading Chart...

Loading Chart...

Areas of Expertise:

Metabotropic Glutamate Receptors

Positive Allosteric Modulators

Negative Allosteric Modulators

Beta-Secretase Inhibitors

Triazole Derivatives

Pyrazole Derivatives

Neurological Disorders

Psychiatric Disorders

Bicyclic Compounds

Heterocyclic Compounds

Indole Derivatives

Aromatic Compounds

53 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12048696 - Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use (2024-07-30),

2. 11369606 - Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use (2022-06-28),

3. 11103506 - Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use (2021-08-31),

4. 11071729 - 1',3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′]bipyridinyl-2′-ones (2021-07-27),

5. 10604523 - 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivatives (2020-03-31),

6. 10584129 - Substituted 6,7-dihydropyrazolo[1,5-a]pyrazines as negative allosteric modulators of mGluR2 receptors (2020-03-10),

7. 10537573 - Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use (2020-01-21),

8. 10519162 - 6,7-dihydropyrazolo[1,5-α]pyrazin-4(5H)-one compounds and their use as negative allosteric modulators of mGluR2 receptors (2019-12-31),

9. 10512646 - Substituted 6,7-dihydropyrazolo[1,5-a]pyrazines as negative allosteric modulators of mGluR2 receptors (2019-12-24),

10. 10112949 - 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one compounds and their use as negative allosteric modulators of mGluR2 receptors (2018-10-30),

11. 10106542 - Substituted 6,7-dihydropyrazolo[1,5-a]pyrazines as negative allosteric modulators of mGluR2 receptors (2018-10-23),

12. 10106524 - 2,3,4,5-tetrahydropyridin-6-amine and 3,4-dihydro-2H-pyrrol-5-amine compound inhibitors of beta-secretase (2018-10-23),

13. 10071095 - 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of neurological and psychiatric disorders (2018-09-11),

14. 10005786 - Substituted 6,7-dihydropyrazolo[1,5-a]pyrazines as negative allosteric modulators of MGLUR2 receptors (2018-06-26),

15. 10005785 - Substituted 6,7-dihydropyrazolo[1,5-a] pyrazines as negative allosteric modulators of mGlUR2 receptors (2018-06-26),

Title: Andrés Avelino Trabanco-Suárez: A Pioneer in Metabotropic Glutamatergic Research

Introduction

Andrés Avelino Trabanco-Suárez, located in Toledo, Spain, is a prolific inventor with a remarkable portfolio of 32 patents to his name. His work primarily focuses on the field of metabotropic glutamatergic receptors, which play a crucial role in various neurological processes.

Latest Patents

His latest innovations involve combinations comprising positive allosteric modulators (PAMs) or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 (mGluR2) and their utilization. The inventions detail combinations that include a PAM of mGluR2 or a pharmaceutically acceptable salt/solvate of such, alongside a synaptic vesicle protein 2A (SV2A) ligand. This work holds potential therapeutic applications, contributing significantly to advancements in pharmacology and neuroscience.

Career Highlights

Andrés has had a distinguished career, with notable contributions while working at Janssen Pharmaceutica N.V. and Janssen Pharmaceuticals, Inc. His expertise in pharmacology and drug design has significantly impacted the development of neurological therapies.

Collaborations

Collaboration has been a key aspect of Andrés’s career. He has worked alongside esteemed colleagues, including José Maria Cid-Núñez and Gary John Tresadern, sharing a vision for innovative solutions in the pharmaceutical industry.

Conclusion

Andrés Avelino Trabanco-Suárez exemplifies the spirit of innovation in the realm of metabotropic glutamatergic research. His contributions, including numerous patents and collaborations with leading professionals, continue to foster advancements in neuroscience and pharmacotherapy, paving the way for future discoveries.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…